Tele: 561.316.3330
Breaking Medical Device News

Monday, September 20, 2021

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR
HomePixie ScientificFDA Registration & U.S. Commercial Launch of Pixie Scientific's Smart Pads for Monitoring Urinary Tract Infections in Incontinent Seniors

FDA Registration & U.S. Commercial Launch of Pixie Scientific’s Smart Pads for Monitoring Urinary Tract Infections in Incontinent Seniors


Scott Meek, Ph.D, head of research and development at Pixie Scientific reports, “We started Pixie Scientific with a big idea—to unobtrusively monitor health conditions.  To see our first product achieve registration with the FDA and begin shipping to our Early Access customers is truly amazing.  No other technology platform is focused on meeting the significant unmet need of UTI monitoring in seniors.”

Pixie Scientific announced today that it has completed the FDA registration for Pixie Smart Pads and has begun shipping to Early Access customers.  The company states that the Class I medical device utilizes a patented sensor and software platform to unobtrusively monitor incontinent seniors for an analyte commonly associated with urinary tract infections (UTIs).

Pixie Scientific is a healthcare platform technology company that focuses on improving outcomes by connecting populations at risk with unobtrusive health monitoring—a field Pixie refers to as Connected Care.  Pixie’s patented platform consists of a biosensor, a mobile app, and secure cloud architecture which utilizes machine learning for analysis and disseminates information to remote care teams.

Clinicians can use this information, along with other symptoms, to order additional patient evaluation or more specific diagnostics in a timely manner—which may lower the rate of co-morbidities and hospital admissions due to UTIs and improve antibiotic stewardship.

For incontinent seniors, particularly those with dementia, communicating the early symptoms of UTIs is problematic and symptoms may only be manifest after a senior becomes agitated, disoriented or falls.  Monitoring for UTIs, in addition to making clinical observations, may help caregivers keep incontinent seniors safe and out of the hospital.

According to the Healthcare Cost and Utilization Project by the Agency for Healthcare Research and Quality (AHRQ), more than 850,000 seniors annually receive the primary diagnosis of UTI in the emergency room.  A third of them are hospitalized with UTI as the primary reason for admission.  At an average cost per hospitalization of $25,000, this is a $7B national problem.  Additional hospitalizations due to falls, dehydration, and delirium caused by the infection, as well as cost of rehabilitation care poses a further burden on families and the healthcare system.

“We started Pixie Scientific with a big idea—to unobtrusively monitor health conditions.  To see our first product achieve registration with the FDA and begin shipping to our Early Access customers is truly amazing,” says Scott Meek, Ph.D, head of research and development at Pixie Scientific.  “No other technology platform is focused on meeting the significant unmet need of UTI monitoring in seniors.”

As part of the Aging 2.0 Alliance, Pixie Scientific is committed to innovating to improve the condition of seniors.  Katy Fike, Ph.D, gerontologist and co-founder of Aging 2.0 said, “Screening for UTIs is particularly important for older adults, especially those with latter stage Alzheimer’s Disease or other dementias.  Smart Pads that enable caregivers to continuously monitor seniors have exciting potential to improve the quality of life and quality of care.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

By using this website you agree to accept Medical Device News Magazine Privacy Policy